ACTIVE

PolyPeptide

Export PDF

Financial year 2025 · closed on 31/12/2025

Net result

7,2 M €

+328.8% YoY

Revenue

156,1 M €

+22.0% YoY

Equity

103,8 M €

+7.4% YoY

Workforce

485,0 ETP

+3.6% YoY

What does PolyPeptide do?

PolyPeptide is a Public limited company incorporated in 2006. Its main activity is: Manufacture of basic pharmaceutical products. Its registered office is in Braine-l'Alleud. It employs on average 485,0 ETP workers (FTE).

Legal situation

● Normal situation

BCE/KBO no. / VAT

BE 0879.346.768

Incorporation

14/02/2006

Legal form

Public limited company

Registered office

Chaussée de Tubize 297
1420 Braine-l'Alleud · WallonieSee on map

Contributed capital

40 000 000,00 €

Latest accounts

31/12/2025

Average workforce

485,0 ETP

Activities (NACE)

21100Manufacture of basic pharmaceutical products· main 21100Manufacture of basic pharmaceutical products 24410Precious metals production 20130Manufacture of other inorganic basic chemicals 20130Manufacture of other inorganic basic chemicals 20140Manufacture of other organic basic chemicals+12

Joint committees (2)

Signals

ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDAHealthy social debtsHigh revenue

View the BCE/KBO Public Search record →

Health score

Available with a Rovalta subscriptionTry for 7 days

Recommended credit limit

✦ Verdict · Analyst summary

Financials

Trend over 19 financial years

	2025		2024		2022		2021		2020		2019		2018		2017		2016		2015		2014		2013		2012		2011		2010		2009		2008		2007		2006
Income statement
Revenue	156,1 M €	+22.0%	127,9 M €	+29.7%	98,7 M €	+54.0%	64,1 M €	+19.0%	53,8 M €	+2.1%	52,7 M €	+7.0%	49,2 M €	-6.0%	52,4 M €	-0.8%	52,8 M €	-7.8%	57,3 M €	+6.0%	54 M €	-18.1%	65,9 M €	+35.6%	48,6 M €	-3.4%	50,3 M €	+9.0%	46,2 M €	-16.1%	55 M €	+12.3%	49 M €	+45.5%	33,7 M €	+20.2%	28 M €
EBITDA	24,7 M €	+151%	9,9 M €	-32.3%	14,5 M €	+2.4%	14,2 M €	+39.5%	10,2 M €	+5.5%	9,6 M €	-5.0%	10,2 M €	+10.4%	9,2 M €	-52.8%	19,5 M €	+116%	9 M €	-29.4%	12,8 M €	-3.4%	13,3 M €	+12.2%	11,8 M €	+12.5%	10,5 M €	+789%	1,2 M €	-77.6%	5,3 M €	-7.6%	5,7 M €	+153%	-10,8 M €	-60.9%	-6,7 M €
Operating result	15,9 M €	+213%	5,1 M €	-27.0%	7 M €	+19.0%	5,9 M €	+14.4%	5,1 M €	-7.5%	5,5 M €	+0.6%	5,5 M €	+114%	2,6 M €	-55.2%	5,7 M €	+40.4%	4,1 M €	-25.7%	5,5 M €	-15.4%	6,5 M €	+4.3%	6,2 M €	+26.1%	4,9 M €	+232%	-3,7 M €	-238%	2,7 M €	+354%	-1,1 M €	+93.3%	-15,7 M €	-62.0%	-9,7 M €
Net result	7,2 M €	+329%	-3,2 M €	-158%	5,4 M €	+11.1%	4,9 M €	+7.8%	4,5 M €	-4.5%	4,8 M €	-6.3%	5,1 M €	+92.7%	2,6 M €	-50.2%	5,3 M €	-14.0%	6,2 M €	-53.7%	13,3 M €	+160%	5,1 M €	+168%	1,9 M €	+353%	421,4 k €	+106%	-7,2 M €	-193%	-2,5 M €	+59.6%	-6,1 M €	+83.4%	-36,8 M €	-183%	-13 M €
Balance sheet
Equity	103,8 M €	+7.4%	96,6 M €	-1.6%	98,1 M €	+5.8%	92,7 M €	+5.5%	87,9 M €	+5.4%	83,4 M €	+6.0%	78,7 M €	+6.8%	73,7 M €	+4.0%	70,8 M €	+8.1%	65,5 M €	+11.1%	59 M €	+29.1%	45,7 M €	+12.6%	40,6 M €	+261%	-25,2 M €	+1.6%	-25,6 M €	-39.5%	-18,3 M €	-15.6%	-15,9 M €	-62.8%	-9,7 M €	-239%	7 M €
Total assets	331,7 M €	+22.4%	271,1 M €	+29.3%	209,6 M €	+43.8%	145,8 M €	+32.2%	110,3 M €	+1.3%	108,9 M €	+9.3%	99,7 M €	+3.0%	96,7 M €	+0.3%	96,4 M €	+5.5%	91,3 M €	-18.2%	111,7 M €	-4.2%	116,6 M €	-1.1%	117,9 M €	+7.3%	109,9 M €	+14.7%	95,9 M €	-6.2%	102,2 M €	-9.8%	113,2 M €	+11.4%	101,7 M €	-15.4%	120,2 M €
Cash	87,1 k €	-71.6%	307,1 k €	-85.1%	2,1 M €	-52.2%	4,3 M €	+262%	1,2 M €	-51.0%	2,4 M €	+195%	820 k €	+29.2%	634,8 k €	-83.0%	3,7 M €	+354%	824,3 k €	-16.7%	989,6 k €	-17.9%	1,2 M €	-66.5%	3,6 M €	+286%	933,2 k €	+158%	361,7 k €	-9.3%	398,8 k €	-80.6%	2,1 M €	+35.0%	1,5 M €	-32.6%	2,3 M €
Debts	226,2 M €	+30.5%	173,3 M €	+57.7%	109,9 M €	+118%	50,5 M €	+133%	21,7 M €	-11.7%	24,5 M €	+25.3%	19,6 M €	-9.4%	21,6 M €	+1.6%	21,2 M €	+0.7%	21,1 M €	-56.5%	48,5 M €	-27.7%	67,1 M €	-8.6%	73,3 M €	-44.4%	132 M €	+12.4%	117,5 M €	+3.5%	113,5 M €	-8.3%	123,8 M €	+17.3%	105,6 M €	-3.7%	109,6 M €
Other
Workforce	485,0 ETP	+3.6%	468,1 ETP	+18.8%	394,0 ETP	+24.2%	317,2 ETP	+19.3%	265,8 ETP	+10.7%	240,1 ETP	+1.0%	237,7 ETP	-8.5%	259,7 ETP	-2.4%	266,1 ETP	-0.9%	268,6 ETP	-5.8%	285,2 ETP	-6.9%	306,5 ETP	-4.9%	322,4 ETP	+0.7%	320,0 ETP	-2.3%	327,6 ETP	-4.2%	342,0 ETP	-0.2%	342,7 ETP	+1.4%	338,1 ETP	+5.8%	319,7 ETP

Estimate

Indicative valuation

As an indication, this company is worth

between 50 M€ and 100 M€

See the valuation

Governance

Board of directors

Seen on filing of 31/12/2025 · 1 active · 33 ended

Active mandates

POLYPEPTIDE LABORATORIES HOLDING ( PPL) AB

Director · since 17 mai 2023 · 0680.977.711

Represented by Raoul Bernhardt

Active

Ended mandates

Polypeptide Laboratories Holding AB

Director · since 17 mai 2023

Represented by Jens Fricke

Ended

Jens Fricke

Director · since 30 janvier 2023 · until 29 janvier 2029

Ended

Jan Furh Miller

Director · since 08 décembre 2022 · until 08 décembre 2028

Ended

Daniel LASANOW

Director · since 17 mai 2022 · until 08 décembre 2022

Ended

Annual accounts

Full financial information

	2025	2024	2023	2022	2021	2020
Type of account	Full model	Full model	Full model	Full model	Full model	Full model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	11/06/2026	03/06/2025	28/05/2024	30/05/2023	09/06/2022	27/05/2021
General meeting	19/05/2026	20/05/2025	21/05/2024	16/05/2023	17/05/2022	18/05/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days

Filings

Annual accounts filings

21 filings with the NBB

Model	Closing	General meeting	Filed	Language	Document
Full model	31/12/2025	19/05/2026	11/06/2026	French	PDF
Full model	31/12/2024	20/05/2025	03/06/2025	French	PDF
Full model	31/12/2023	21/05/2024	28/05/2024	French	PDF
Full model	31/12/2022	16/05/2023	30/05/2023	French	PDF
Full model	31/12/2021	17/05/2022	09/06/2022	French	PDF
Full model	31/12/2020	18/05/2021	27/05/2021	French	PDF
Full model	31/12/2019	19/05/2020	04/06/2020	French	PDF
Full modelCorrection	31/12/2018	21/05/2019	02/09/2019	French	PDF
Full model	31/12/2018	21/05/2019	18/07/2019	French	PDF
Full model	31/12/2017	15/05/2018	25/06/2018	French	PDF
Full model	31/12/2016	30/06/2017	13/07/2017	French	PDF
Full model	31/12/2015	17/05/2016	10/06/2016	French	PDF
Full model	31/12/2014	19/05/2015	11/06/2015	French	PDF
Full model	31/12/2013	20/05/2014	23/06/2014	French	PDF
Full model	31/12/2012	21/05/2013	25/06/2013	French	PDF
Full model	31/12/2011	15/05/2012	27/06/2012	French	PDF
Full model	31/12/2010	17/05/2011	29/06/2011	French	PDF
Full model	31/12/2009	18/05/2010	21/06/2010	French	PDF
Full model	31/12/2008	19/05/2009	23/06/2009	French	PDF
Full model	31/12/2007	20/05/2008	20/06/2008	French	PDF
Full model	31/12/2006	15/05/2007	22/06/2007	French	PDF

Estimate

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 50 M€ and 100 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2025 · 1 active · 33 ended

Active mandates

POLYPEPTIDE LABORATORIES HOLDING ( PPL) AB

Director · since 17 mai 2023 · 0680.977.711

Represented by Raoul Bernhardt

Active

Ended mandates

Polypeptide Laboratories Holding AB

Director · since 17 mai 2023

Represented by Jens Fricke

Ended

Jens Fricke

Director · since 30 janvier 2023 · until 29 janvier 2029

Ended

Jan Furh Miller

Director · since 08 décembre 2022 · until 08 décembre 2028

Ended

Daniel LASANOW

Director · since 17 mai 2022 · until 08 décembre 2022

Ended

Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette

Belgian Official Gazette publications

Mandates18/11/2025
DEMISSIONS, NOMINATIONS
PDF
Mandates18/06/2024
DEMISSIONS, NOMINATIONS
PDF
Mandates02/04/2024
DEMISSIONS, NOMINATIONS
PDF
Mandates13/06/2023
DEMISSIONS, NOMINATIONS
PDF
Mandates23/03/2023
DEMISSIONS, NOMINATIONS
PDF
Mandates28/12/2022
DEMISSIONS, NOMINATIONS
PDF
Mandates14/06/2022
DEMISSIONS, NOMINATIONS
PDF
Other29/12/2021
STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, )
PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

2025
Annual accounts 20257,2 M €↑
01/10/2025
nominationRaoul BERNHARDT — représentant permanent de l'administrateur unique
2024
Annual accounts 2024-3,2 M €↓
21/05/2024
reconductionBDO Réviseurs d'Entreprises SRL — commissaire
21/05/2024
nominationRodrigo ABELS — représentant permanent chargé de l'exercice de son mandat
17/05/2023
nominationPolyPeptide Laboratories Holding (PPL) AB — administrateur unique
17/05/2023
nominationJens FRICKE — représentant permanent
30/01/2023
nominationJens FRICKE — administrateur
2022
Annual accounts 20225,4 M €↑
08/12/2022
nominationJan Fuhr MILLER — administrateur
17/05/2022
reconductionDaniel LASANOW — administrateur
2021
Annual accounts 20214,9 M €↑
30/11/2021
nominationVincenzo Mancuso — administrateur délégué
2020
Annual accounts 20204,5 M €↓
2019
Annual accounts 20194,8 M €↓
2018
Annual accounts 20185,1 M €↑
2017
Annual accounts 20172,6 M €↓
2016
Annual accounts 20165,3 M €↓
2016
Name changePolyPeptide SA
2015
Annual accounts 20156,2 M €↓
2014
Annual accounts 201413,3 M €↑
2013
Annual accounts 20135,1 M €↑
2012
Annual accounts 20121,9 M €↑
2011
Annual accounts 2011421,4 k €↑
2010
Annual accounts 2010-7,2 M €↓
2009
Annual accounts 2009-2,5 M €↑
2008
Annual accounts 2008-6,1 M €↑
2007
Annual accounts 2007-36,8 M €↓
2006
Annual accounts 2006-13 M €
14/02/2006
IncorporationPublic limited company
2006
Name changeLONZA BRAINE

10/15	1 240 000	1 180 000	1 050 000
70	8 630 000	8 120 000	7 940 000
9904	412 000	388 000	301 000
17/49	2 970 000	3 140 000	3 380 000
9087	24,3	23,1	21,8

PolyPeptide

Overview

What does PolyPeptide do?

Trend over 19 financial years

Indicative valuation

Board of directors

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline